Massimo Calafiore

Massimo Calafiore (chief executive) discloses dealings in 2 companies, chiefly Orthofix Medical Inc. and Nuvasive Inc. Over a trading history stretching from 30 April 2021 to 4 March 2026, the count stands at 13 filings.

Market trades split into 2 purchases (€274k) and 5 sales (€684k). The net balance comes to €410k on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 3 share grants and 3 option exercises. So far in 2026, the count stands at no purchases and 3 sales.

The latest filing, published on 6 March 2026, reports an open-market sale of €69k in Orthofix Medical Inc. The last purchase on record was published on 12 May 2025, which is 524 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.